Neurology
French Registry Data Show Marked Declines in Relapse Activity and Faster Diagnosis in AQP4+NMOSD and MOGAD From 2010 to 2024
A nationwide French cohort found earlier diagnosis, falling relapse rates, and major treatment shifts in AQP4+NMOSD and MOGAD, with rituximab linked to lower disability risk in AQP4+NMOSD and overall milder disability trajectories in MOGAD.
